NS Pharma recognizes the greatest partnerships flourish when built on a foundation of integrity and open communication. We partner with international best-in-class organizations and medical facilities to ensure operational excellence that leverages our collective experience and expertise to better serve our patients and address the most pressing needs of the rare disease community.
For more than a century our parent company, Nippon Shinyaku Co., Ltd., has been cultivating comprehensive expertise in the development of pharmaceutical drugs fueled by scientific innovation. NS Pharma and Nippon Shinyaku maintain a robust pipeline of novel modalities, including gene and cell therapies. Contact us today to discuss how our partnership could benefit patients.
Together, Nippon Shinyaku and NS Pharma are dedicated to furthering scientific research and the delivery of rare disease treatments for patients in need across the world, from the United States to the European Union and Asia. Our global partnerships are central to our ability to advancing therapeutic innovation and expanding access, addressing the critical needs of patients worldwide.
Business Development, located in Paramus, New Jersey, focuses on partnering for clinical-stage programs and actively communicates with biotech companies in the U.S. and EU. Innovation Research Partnering, based in Cambridge, Massachusetts, aims to establish technology collaborations or partnerships for preclinical-stage programs, engaging with biotech companies and academia in the U.S. and EU.
